Sponsored Taskade - Plan projects, collaborate, and build AI agents and automations in connected team workspaces. Sponsored Synthesys X - Search an image or describe an idea, then generate visual variations and supporting creative assets in… Sponsored Simplified - Create marketing copy, designs, videos, social posts, and campaign assets in one AI-assisted workspace. Sponsored Scalenut - Plan, create, optimize, and monitor search content with AI-assisted SEO and generative-engine workflows. Sponsored Rytr - AI writing assistant for drafting, rewriting, expanding, and refining everyday marketing and business content. Sponsored Pictory - Pictory is a cloud AI video-production platform for converting scripts, articles, URLs, presentations, and long recordings… Sponsored Murf AI - Murf AI provides text-to-speech, voiceover, dubbing, translation, and conversational voice-agent capabilities for business and creative use. Sponsored MeetGeek - MeetGeek is an AI meeting assistant for recording, transcription, summaries, search, analytics, workflows, integrations, and voice… Sponsored Frase - Frase provides SEO research, content briefs, writing, optimization, and AI-assisted content workflows. Sponsored Fliki - Fliki creates videos, voiceovers, avatars, translations, and other media from scripts and ideas. Sponsored Fireflies.ai - Fireflies.ai records, transcribes, summarizes, searches, and analyzes meetings and conversations. Sponsored Browse AI - Browse AI extracts and monitors website data through no-code robots, schedules and integrations. Sponsored ArtSmart AI - ArtSmart AI generates images and provides creative editing tools.
Menu Close
Visit Tool
Neuproscan
☆☆☆☆☆
Data Analysis (296)

Neuproscan Verified Tool

Neuproscan develops AI methods for detecting pre-clinical Alzheimer’s disease patterns from MRI data for research and clinical-support contexts.

Last Update: August 20, 2026

Visit Tool

Starting price Custom pricing

Tool Information

Neuproscan develops AI methods for detecting pre-clinical Alzheimer’s disease patterns from MRI data for research and clinical-support contexts.

Qualified organizations use validated imaging protocols, obtain consent, assess performance across populations, keep specialists responsible for interpretation, and follow regulatory and research requirements.

Commercial or research pricing is customized by studies, scans, deployment, validation, and services.

Medical imaging AI can miss disease, create false alarms, or perform unevenly across populations. It is not self-diagnosis; clinical validation, privacy, regulation, and specialist oversight are mandatory.

F.A.Q (3)

Neuproscan develops AI methods for detecting pre-clinical Alzheimer’s disease patterns from MRI data for research and clinical-support contexts.

Qualified organizations use validated imaging protocols, obtain consent, assess performance across populations, keep specialists responsible for interpretation, and follow regulatory and research requirements.

Verified pricing: Custom pricing. Commercial or research pricing is customized by studies, scans, deployment, validation, and services.

Pros and Cons

Pros

  • NeuProScan explores early Alzheimer's risk signals from a single MRI scan
  • The system automatically selects relevant MRI slices
  • Axial; coronal; and sagittal views can contribute to the model
  • Up to nine slices keep the input set computationally compact
  • Different slice combinations accommodate varying scan sets
  • The site explains the slice-selection concept in accessible language
  • Active models are listed publicly
  • Model pages expose performance-oriented information
  • Training-history charts include accuracy
  • Validation accuracy helps compare performance beyond training data
  • Loss and validation-loss curves can reveal overfitting
  • The platform is described as customizable for different organizations
  • The research approach may assist investigation of preclinical markers
  • MRI-based analysis avoids introducing a new invasive sampling procedure
  • Continuous training is intended to improve future model versions
  • The prominent disclaimer clearly limits the current system to research use

Cons

  • NeuProScan is expressly not intended for medical diagnosis
  • The software must not guide treatment decisions
  • Its predictions cannot replace professional medical advice
  • A high-risk classification does not prove that dementia will develop
  • A low-risk result cannot rule out future Alzheimer's disease
  • Performance can change across scanners; protocols; and patient populations
  • Selecting only nine slices may omit relevant anatomy elsewhere in the scan
  • Training and validation metrics do not establish prospective clinical utility
  • Repeated model updates can change results for similar cases
  • MRI files contain highly sensitive health information
  • Demographic bias may reduce accuracy for underrepresented groups
  • Incidental findings require qualified radiological review
  • Early risk information can cause anxiety without appropriate counseling
  • Hospitals need ethics; privacy; and research-governance approval before use
  • Clinical adoption would require regulatory clearance and external validation
  • Patients should discuss cognitive concerns with a licensed clinician rather than this research website

Reviews

You must be logged in to submit a review.

No reviews yet. Be the first to review!

Overview

Pricing
Paid

Applicable Tasks

dementia predictions health MRI

Before you subscribe

  • Check the currency, billing period, automatic renewal, usage limits and seats at checkout — prices and promotions change.
  • App-store pricing can differ from website pricing by country, device and tax.
  • Share only authorised data, and read the provider's encryption, retention and model-training terms first.
  • AI output can be incomplete or wrong. Verify facts, citations, calculations and code before you publish or ship.
  • Commercial usage rights vary by plan, provider terms and jurisdiction.
  • None of these tools replaces a qualified professional for medical, legal or financial decisions.

Disclaimer · How we review tools

Quick actions
Visit Tool